for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NanoCarrier Co., Ltd.

4571.T

Latest Trade

297.00JPY

Change

5.00(+1.71%)

Volume

178,800

Today's Range

291.00

 - 

297.00

52 Week Range

269.00

 - 

454.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
292.00
Open
291.00
Volume
178,800
3M AVG Volume
14.48
Today's High
297.00
Today's Low
291.00
52 Week High
454.00
52 Week Low
269.00
Shares Out (MIL)
69.88
Market Cap (MIL)
20,405.59
Forward P/E
-11.32
Dividend (Yield %)
--

Next Event

Q1 2022 NanoCarrier Co Ltd Earnings Release

Latest Developments

More

NanoCarrier signs exclusive agreement for global study on new approach of using NC-6004 to treat head and neck cancer

NanoCarrier signs joint-development contract with Ceolia Pharma

NanoCarrier says basic agreement on international joint development of NC-6004 to treat head and neck cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NanoCarrier Co., Ltd.

NanoCarrier Co., Ltd. is a Japan-based biopharmaceutical products developer. The Company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It is engaged in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The Company’s product candidates include cisplatin micelle (NC - 6004), DACH-platin micelle (NC - 4016), epirubicin micelle (NC - 6300) and paclitaxel micelle (NK 105).

Industry

Biotechnology & Drugs

Contact Info

Ohnoya Kyobashi Bldg., 1-4-10, Kyobashi

CHUO-KU, TKY

104-0031

Japan

+81.3.32410550

http://www.nanocarrier.co.jp

Executive Leadership

Tetsuhito Matsuyama

President, Chief Executive Officer, Representative Director

Takuma Nakatsuka

Chief Financial Officer, Director of Administration, Manager of President's Office, Board of Director

Hiroyuki Hanada

Chief Operating Officer, Director of Business Development, Director

Yasuki Kato

Chief Scientific Officer, Director

Ichiro Nakatomi

Director

Key Stats

1.00 mean rating - 1 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
--
Price To Sales (TTM)
65.14
Price To Book (MRQ)
2.72
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.68
Return on Equity (TTM)
-33.83

Latest News

Latest News

BRIEF-Vascular Biogenics Ltd Intends To Extend Ongoing Global Phase 3 Oval Clinical Trial In Ovarian Cancer To Patients In Japan

* VASCULAR BIOGENICS LTD - INTENDS TO EXTEND ONGOING GLOBAL PHASE 3 OVAL CLINICAL TRIAL IN OVARIAN CANCER TO PATIENTS IN JAPAN

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up